ArticleEmerging infectious diseases2018
World Health Organization Methodology to Prioritize Emerging Infectious Diseases in Need of Research and Development.
Article in Emerging infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical laboratory parameters and fatality of Severe fever with thrombocytopenia syndrome patients: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2022Pooled it
- A Rapid Literature Review of Multi-Criteria Decision Support Methods in the Context of One Health for All-Hazards Threat Prioritization.Frontiers in public health · 2022Pooled it
- Dissecting the evolutionary forces shaping codon usage bias in SFTSV from eastern China: Insights from a previously underrepresented region.Virulence · 2026Article
- Integrating mathematical modelling and artificial intelligence to combat emerging viral syndemics: A systematic review.New microbes and new infections · 2026Review
- Prioritization of zoonoses for health professional knowledge building in Canada.Canadian journal of public health = Revue canadienne de sante publique · 2026Article
- Dual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity.Scientific reports · 2026Article
- Structural and mechanistic insights into protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus nucleocapsid protein.Nature communications · 2026Article
- Strengthening India's pandemic preparedness with the four zonal institutes of virology: stakeholder consultations for outbreak response and collaborative research priorities.Infectious diseases of poverty · 2026Article
- Welcome to the jungle: collection and evaluation of quality indicators with the QUALICATOR instrument.BMJ quality & safety · 2026Article
- Targeting the lethal weakness of SFTSV: Latest advances in antiviral strategies and immune prevention.iScience · 2026Review
- Epidemiological Features and Environmental Factors of Severe Fever with Thrombocytopenia Syndrome Patients in a Highly Endemic Region: A 12-Year Surveillance Study.Pathogens (Basel, Switzerland) · 2026Article
- Structure and function of the nairovirus cap-snatching endonuclease.Nucleic acids research · 2026Article
- Immunoreactivity of pan MHC-I epitopes on Crimean-Congo hemorrhagic fever virus glycoprotein C-terminal.Frontiers in immunology · 2026Article
- The Red Cell Distribution Width to Albumin Ratio as a Novel Prognostic Predictor in Patients with Severe Fever with Thrombocytopenia Syndrome: A Multicenter Study in China.Infection and drug resistance · 2026Article
- Boswellic Acid Derivatives: A Traditional and Multifunctional Therapeutic Agent for Infectious and Non-Infectious Diseases - A Comprehensive Review.Chemistry & biodiversity · 2026Review
- Generation of an Etiology Index Based on Confirmed Tissue Diagnosis Data to Assess Endemic Swine Etiology Activity in the United States of America.Transboundary and emerging diseases · 2026Article
- Evolution and the potential for human-to-human transmission of severe fever with thrombocytopenia syndrome virus in low transmission settings in China.New microbes and new infections · 2025Article
- Current status of severe fever with thrombocytopenia syndrome in China (Review).International journal of molecular medicine · 2025Review
- Therapeutic Vaccines for Non-Communicable Diseases: Global Progress and China's Deployment Pathways.Vaccines · 2025Review
- Age-associated immune dysregulation and B cell dysfunction drive severe outcomes in SFTSV infection.PLoS pathogens · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization R&D Blueprint aims to accelerate the availability of medical technologies during epidemics by focusing on a list of prioritized emerging diseases for which medical countermeasures are insufficient or nonexistent. The prioritization process has 3 components: a Delphi process to narrow down a list of potential priority diseases, a multicriteria decision analysis to rank the short list of diseases, and a final Delphi round to arrive at a final list of 10 diseases. A group of international experts applied this process in January 2017, resulting in a list of 10 priority diseases. The robustness of the list was tested by performing a sensitivity analysis. The new process corrected major shortcomings in the pre-R&D Blueprint approach to disease prioritization and increased confidence in the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.